Liu 2019d.

Methods	Study design: Randomised clinical trial Study duration: January 2016 to January 2018 Duration of follow‐up: 3 months Setting: Hospital
Participants	Number of participants: 76 Inclusion criteria: Diagnosed as HCC; advanced tumour; Child‐Pugh Class A or B Age (mean ± SD, range ): TACE + MWA: 58.4 ± 4.5 years; TACE alone: 58.2 ± 4.4 years Male (n/total): TACE + MWA: 27/38; TACE alone: 26/38
Interventions	TACE + MWA group (n = 38) Control group (n = 38)
Outcomes	Tumour response: measured by contrast‐enhanced CT at 4 and 12 weeks after treatment
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.